Table of Content

1. Introduction To STAT3 Inhibitors


2. STAT3 Inhibition Approaches
2.1 Direct Inhibition
2.2 Indirect Inhibition


3. Role Of STAT3 Inhibitors By Indication & Clinical Development Scenario
3.1 Cancer
3.1.1 Breast Cancer
3.1.2 Pancreatic Cancer
3.1.3 Lung Cancer
3.1.4 Melanoma
3.1.5 Lymphoma
3.1.6 Leukemia
3.2 Autoimmune & Inflammatory Diseases
3.3 Microbial Infections


4. Therapeutic Approaches For STAT3 Inhibition
4.1 Targeted Therapy With STAT3 Inhibitors
4.2 Monotherapy With STAT3 Inhibitors
4.3 Combination Therapies With STAT3 Inhibitors


5. Global STAT3 Inhibitors Market Outlook
5.1 Current Clinical Development & Commercialization Scenario
5.2 Future Trends Analysis


6. Global STAT3 Inhibitors Clinical Pipeline Overview
6.1 By Country
6.2 By Indication
6.3 By Organization
6.4 By Phase


7. Global STAT3 Inhibitors Clinical Pipeline By Company, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Preregistration


8. Marketed STAT3 Inhibitor Drug Clinical & Patent Insight


9. STAT3 Inhibitors Market Dynamics
9.1 Drivers & Opportunities
9.2 Challenges & Restraints


10. Competitive Landscape
10.1 Accendatech
10.2 Baylor College of Medicine
10.3 C&C Research Laboratories
10.4 Daewoong Pharmaceutical
10.5 Entero Therapeutics
10.6 GLG Pharma
10.7 Hanlim Pharmaceutical
10.8 Immix Biopharma
10.9 Institut Pasteur Korea
10.10 Ionis Pharmaceuticals
10.11 Jiangsu Hengrui Medicine Co.
10.12 Kymera Therapeutics
10.13 Moleculin
10.14 NeuroBo Pharmaceuticals
10.15 NovoMedix
10.16 Singh Biotechnology
10.17 Sumitomo Pharma
10.18 Tvardi Therapeutics
10.19 UNION Therapeutics
10.20 University of Texas M. D. Anderson Cancer Center
 



List of Figures

Figure 1-1: Structure Of Stattic
Figure 1-2: STAT3 Inhibitors - Development Timeline

Figure 2-1: Direct & Indirect Mechanisms Of STAT3 Inhibition
Figure 2-2: Classification Of STAT3 Inhibitors Based On Type
Figure 2-3: Advantages & Disadvantages Of Peptide-Based Inhibitors
Figure 2-4: Napabucasin - Mechanism Of Action

Figure 3-1: Breast Cancer Treatment Resistance - STAT3-Associated Pathways
Figure 3-2: IMX-110-001 Phase I/II (NCT03382340) Study – Initiation & Completion Year
Figure 3-3: Phase I (NCT05440942) Study – Initiation & Completion Year
Figure 3-4: Effects of STAT3 Hyperactivation
Figure 3-5: Phase I (NCT03195699) Study – Initiation & Completion Year
Figure 3-6: Phase I (NCT03195699) Study – Initiation & Completion Year
Figure 3-7: Causes & Effects Of Dysregulated STAT3 Signaling
Figure 3-8: KT333-TL-101 Phase I (NCT05225584) Study – Initiation & Completion Year
Figure 3-9: Phase I (NCT04049825) Study – Initiation & Completion Year
Figure 3 10: Global - Estimated Leukemia Incidences & Deaths (Thousand), 2022

Figure 4-1: Mechanism Of Action Of EGFR Inhibitors

Figure 5-1: Global – STAT3 Inhibitor Drug Market Opportunity Assessment (US$ Million)
Figure 5-2: Global STAT3 Inhibitor Market – Guiding Factors For Future

Figure 6-1: Global – Number Of STAT3 Inhibitors Clinical Trials By Country, 2025 Till 2028
Figure 6-2: Global – Number Of STAT3 Inhibitors Clinical Trials By Indication, 2025 Till 2028
Figure 6-3: Global – Number Of STAT3 Inhibitors Clinical Trials By Organization, 2025 Till 2028
Figure 6-4: Global – Number Of STAT3 Inhibitors Clinical Trials By Phase, 2025 Till 2028

Figure 9-1: Global STAT3 Inhibitors Market - Drivers
Figure 9-2: Global STAT3 Inhibitors Market - Challenges
 

List of Tables

Table 3-1: Breast Cancer - STAT3 Inhibitors Under Investigation
Table 3-2: Pancreatic Cancer - STAT3 Inhibitors Under Investigation
Table 3-3: Lung Cancer - STAT3 Inhibitors Under Investigation
Table 3-4: Melanoma - STAT3 Inhibitors Under Investigation
Table 3-5: Lymphoma - STAT3 Inhibitors Under Investigation